Revenio Group Corporation: Appointments in Revenio Group's Management Team
Revenio Group Corporation: Stock Exchange Release, January 24, 2018 at 9.00
Appointments in Revenio Group's Management Team
As of February 1st, 2018, QA Manager, M.Sc., Heli Valtanen and R&D Director, M.Sc. Mika Salkola from Icare Finland Ltd will be appointed as members of Revenio Group's Management Team. Valtanen will also be appointed as QA Director to Revenio Group and Mika Salkola will be appointed as R&D Director to Revenio Research Oy, as the current position holder, M.Sc. (Tech) Ari Kukkonen will move to part-time retirement. Ari Kukkonen continues as Senior Advisor and member of Extended Management Team at Revenio Group.
Heli Valtanen has held the position of QA Manager at Icare Finland since 2010. Previously Heli has worked as QA Manager at Plexpress Oy, as CTO at CTT Cancer Targeting Technologies Ltd and as Research Scientist at University of Helsinki, Haartman Institute.
Mika Salkola has worked as R&D Director of Icare Finland since September 2015. Mika has extensive experience in R&D. He has over 20 years of experience in international R&D operations, among others at Thermo Fisher Scientific and Vaisala.
"I am happy to welcome Heli and Mika as members of our Management Team. They both have demonstrated strong knowledge in their areas of responsibilities and are valuable reinforcements in Revenio Group's Management Team. Both quality and R&D play a significant role in our pursuit of the position as the global leader in health technology related screenings", states the CEO of Revenio Group, Timo Hildén.
The Management Team of Revenio Group will be as of February 1st 2018: Revenio Group's CEO Timo Hildén (Chairman), Revenio Group's CFO Robin Pulkkinen, Icare Finland Ltd's Sales and Marketing Director Tomi Karvo, Revenio Research Oy's R&D Director Mika Salkola, Icare Finland Ltd's Operations Director Ari Isomäki and Icare Finland Ltd's QA Manager Heli Valtanen. Furthermore, Tiina Olkkonen is attending Management Team meetings as an external communication specialist and Management Team secretary. In addition of the Management Team members, Senior Advisor of Revenio Group Ari Kukkonen and CEO of Icare USA Inc John Floyd are members of the Group's Extended Management Team.
Revenio Group Corporation
For further information, please contact:
Timo Hildén, President & CEO, tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi
www.ventica.fi
DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2016, Revenio Group's net sales totaled MEUR 23,4, with its operating margin for continuing operations standing at 30,1%. Revenio Group Corporation is listed on Nasdaq Helsinki.